Yasuaki Anami

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 12

Top Venues

Nature reviews. Clinical oncology

Nature communications

Molecular cancer therapeutics

Journal of medicinal chemistry

Japan Society for the Promotion of Science

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Japan Society for the Promotion of Science Apr 01 2019

Japan

JSPS Overseas Research Fellow

University of Texas Health Science Center at Houston

United States

Postdoctoral fellow :: The Brown Institute of Molecular Medicine

Publications

Kyoji Tsuchikama, Yasuaki Anami, Summer Y Y Ha, Chisato M Yamazaki
Exploring the next generation of antibody-drug conjugates. Nature reviews. Clinical oncology (2024)
Kyoji Tsuchikama, Yasuaki Anami, Summer Y Y Ha, Chisato M Yamazaki
Exploring the next generation of antibody-drug conjugates. Nature reviews. Clinical oncology 21 (3) (2024)
Kyoji Tsuchikama, Yasuaki Anami, Summer Y Y Ha, Chisato M Yamazaki
Exploring the next generation of antibody-drug conjugates. Nature reviews. Clinical oncology 21 (3) (2024)
Kyoji Tsuchikama, Yasuaki Anami, Summer Y Y Ha, Chisato M Yamazaki
Exploring the next generation of antibody-drug conjugates. Nature reviews. Clinical oncology 21 (3) (2024)
Summer Y Y Ha, Yasuaki Anami, Chisato M Yamazaki, Wei Xiong, Candice M Haase, Scott D Olson, Jangsoon Lee, Naoto Tada Ueno, Ningyan Zhang, Zhiqiang An, Kyoji Tsuchikama
An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates. Molecular cancer therapeutics 21 (9) (2022)
Yasuaki Anami, Wei Xiong, Aiko Yamaguchi, Chisato M Yamazaki, Ningyan Zhang, Zhiqiang An, Kyoji Tsuchikama
Homogeneous antibody-angiopep 2 conjugates for effective brain targeting. RSC advances 12 (6) (2022)
Chisato M Yamazaki, Aiko Yamaguchi, Yasuaki Anami, Wei Xiong, Yoshihiro Otani, Jangsoon Lee, Naoto Tada Ueno, Ningyan Zhang, Zhiqiang An, Kyoji Tsuchikama
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nature communications 12 (1) (2021)
Kyriacos C Nicolaou, Qifeng Chen, Ruofan Li, Yasuaki Anami, Kyoji Tsuchikama
Total Synthesis of the Monomeric Unit of Lomaiviticin A. Journal of the American Chemical Society 142 (47) (2020)
Yasuaki Anami, Mi Deng, Xun Gui, Aiko Yamaguchi, Chisato M Yamazaki, Ningyan Zhang, Zhiqiang An, Kyoji Tsuchikama
LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia. Molecular cancer therapeutics 19 (11) (2020)
Xun Gui, Mi Deng, Hao Song, Yuanzhi Chen, Jingjing Xie, Zunling Li, Licai He, Fangfang Huang, Yixiang Xu, Yasuaki Anami, Hai Yu, Chenyi Yu, Leike Li, Zihao Yuan, Xiaoying Xu, Qihui Wang, Yan Chai, Tao Huang, Yi Shi, Kyoji Tsuchikama, X Charlene Liao, Ning-Shao Xia, George F Gao, Ningyan Zhang, Cheng Cheng Zhang, Zhiqiang An
Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development. Cancer immunology research 7 (8) (2019)
Mami Yoshizawa, Toshimasa Itoh, Tatsuya Hori, Akira Kato, Yasuaki Anami, Nobuko Yoshimoto, Keiko Yamamoto
Identification of the Histidine Residue in Vitamin D Receptor That Covalently Binds to Electrophilic Ligands. Journal of medicinal chemistry 61 (14) (2018)
Yasuaki Anami, Chisato M Yamazaki, Wei Xiong, Xun Gui, Ningyan Zhang, Zhiqiang An, Kyoji Tsuchikama
Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. Nature communications 9 (1) (2018)

Yasuaki Anami.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yasuaki Anami